US5641753AExpiredUtility
10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives combined with sulfisoxazole
Individually held — no corporate assignee on recordPriority: Mar 25, 1996Filed: Mar 25, 1996Granted: Jun 24, 1997
Est. expiryMar 25, 2016(expired)· nominal 20-yr term from priority
Inventors:Chris Platt
A61K 31/70C07H 17/08
31
PatentIndex Score
5
Cited by
6
References
5
Claims
Abstract
Pharmaceutical compositions of an erythromycin derivative combined with sulfisoxazole according to the structural formulas: ##STR1## where R is hydrogen, C1-C10 alkylcarbonyl or C1-C10 alkyl wherein the substituent is amino or cyano; R1 and R2 are independently hydrogen, hydroxyl or amino; and the pharmaceutical salts and esters thereof.
Claims
exact text as granted — not AI-modifiedI claim:
1. A pharmaceutical composition containing an erythromycin derivative in combination with an acetylsulfisoxazole according to the structural formulas: ##STR3## wherein R is hydrogen, C1-C10 alkylcarbonyl, or substituted C1-C10 alkyl, wherein said substituent is amino or cyano; R 1 and R 2 are independently hydrogen, hydroxyl or amino; and pharmaceutical salts and esters thereof.
2. A pharmaceutical composition of a erythromycin derivative combined with acetylsulfisoxazole according to the structural formula: ##STR4## and the pharmaceutically acceptable salts, esters and metal complexes thereof, wherein R 1 is hydrogen, C1-C10 alkylcarbonyl or unsubstituted or substituted C1-C10 alkyl wherein said substituent is amino or cyano; R 2 and R 3 are hydrogen; R 2 and R 3 together are oxo; R 4 is hydrogen or C1-C10 alkylcarbonyl; R 5 and R 6 are independently hydrogen, hydroxy or amino; R 5 and R 6 together are oxo or oximino; R 7 and R 8 are independently hydrogen, C1-C10 alkyl or phenylsulfonyl; R 9 is hydrogen, or C1-C10 alkylcarbony, R 10 is hydrogen, and R 11 is hydrogen or acetyl.
3. The composition of claim 1, wherein the erythromycin derivative has the structural formula: ##STR5## wherein R is methyl, R 1 is H and R 2 is OH.
4. The composition of claim 1, wherein the erythromycin derivative has the structural formula: ##STR6## wherein R is amino alkyl carbonyl, R 1 is H and R 2 is OH.
5. The composition of claim 1, wherein the erythromycin derivative has the structural formula: ##STR7## wherein R is cyano, R 1 is an amino group, and R 2 is H.Join the waitlist — get patent alerts
Track US5641753A — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.